Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 4Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Specimen Handling 334Magnetic Resonance Spectroscopy 334Radiotherapy 315Cyclophosphamide 295pembrolizumab 281Cisplatin 267Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 204Bevacizumab 186Gemcitabine 178venetoclax 172Radiosurgery 169Capecitabine 164Oxaliplatin 163fludarabine 161Nivolumab 156Paclitaxel 155Standard of Care 136Surveys and Questionnaires 130Surgical Procedures, Operative 130Dexamethasone 126Fluorouracil 124Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104Azacitidine 101atezolizumab 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER × 5-aminolevulinic acid hexyl ester × Clear all
NCT05962541 2025-12-31

CUT-less

University of Roma La Sapienza

Phase 4 Recruiting
327 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06525571 2025-11-18

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Johns Hopkins University

Phase 3 Recruiting
200 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡